A review on the advancement of polydopamine (PDA)-based nanomaterials for cancer treatment
- PMID: 40237855
- DOI: 10.1007/s12032-025-02678-5
A review on the advancement of polydopamine (PDA)-based nanomaterials for cancer treatment
Abstract
The significance of cancer treatment research lies in addressing the high incidence of cancer, overcoming treatment challenges, and mitigating the harsh side effects of chemotherapeutic agents. Currently, nanotechnology is garnering significant attention for its potential applications in diagnostics and drug delivery, offering innovative solutions for disease detection and treatment. Among different types of nanoparticles (NPs), polymeric nanoparticles comprise biocompatible and biodegradable polymers that enhance drug pharmacokinetics and pharmacodynamics, minimize adverse effects, increase stability, and facilitate sustained drug release. These polymeric nanoparticle-based nanomedicines offer a versatile platform for various cancer treatments, notably enabling targeted drug delivery directly to tumors, tumor-imaging, hyperthermia, and photodynamic therapy. Being polymeric in nature polydopamine (PDA) nanomaterials are appeared as promising approaches in biology and medicine. This review article offers a concise summary of the latest developments in polydopamine-based cancer treatment, covering key findings, limitations, and emerging trend therapeutic approach of polydopamine nanomaterials, along with the properties and various methods of preparation. Physico-chemical properties of PDA-based nanomaterials in therapeutics have permitted several successful modifications in the field of cancer treatment.
Keywords: Cancer therapy; Drug delivery system; Photothermal activity; Polydopamine; Polymeric nanoparticles.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: This article does not involve ethics. Research involving human and animal participants: No Animals/Humans were used for studies that are basis of this research. Consent to participate: This article does not involve ethics.
References
-
- Harish V, Tewari D, Gaur M, Yadav AB, Swaroop S, Bechelany M, Barhoum A. Review on nanoparticles and nanostructured materials: bioimaging, biosensing, drug delivery, tissue engineering, antimicrobial, and agro-food applications. Nanomaterials. 2022;12(3):457. https://doi.org/10.3390/nano12030457 . - DOI - PubMed - PMC
-
- Zheng X, Zhang P, Fu Z, Meng S, Dai L, Yang H. Applications of nanomaterials in tissue engineering. RSC Adv. 2021;11(31):19041–58. https://doi.org/10.1039/D1RA01849C . - DOI - PubMed - PMC
-
- Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:93. https://doi.org/10.3389/fmolb.2020.00193 . - DOI
-
- Ioele G, Chieffallo M, Occhiuzzi MA, De Luca M, Garofalo A, Ragno G, Grande F. Anticancer drugs: recent strategies to improve stability profile, pharmacokinetic and pharmacodynamicproperties. Molecules. 2022;27(17):5436. https://doi.org/10.3390/molecules27175436 . - DOI - PubMed - PMC
-
- Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin FH, Qoronfleh MW. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23(1):1–29. https://doi.org/10.1186/s40824-019-0166-x . - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical